Mazzuca, FedericaBotticelli, AndreaMazzotti, EvaLa Torre, MarcoBorro, MarinaMarchetti, LucaMaddalena, ChiaraGentile, GiovannaSimmaco, MaurizioMarchetti, Paolo2023-02-212023-02-212016-01-0110.5152/eurasianjmed.2015.008https://hdl.handle.net/11443/1969http://dx.doi.org/10.5152/eurasianjmed.2015.008Objective: Third-generation aromatase inhibitors (AI) are potent suppressors of aromatase activity. The aim of this study was to measure the incidence of adverse effects in breast cancer patients treated with AI-based adjuvant therapy and the relationship with the CYP19A1 genotypes. Materials and Methods: Forty-five postmenopausal breast cancer patients (46-85 yrs) in AI adjuvant treatment were genotyped for the rs4646 polymorphisms of CYP19A1 gene and three variations were identified. Toxicities were registered at each follow-up medical examination, and classified in accord with the Common Terminology Criteria for Adverse Events. Results: Twenty-four (53.3\%) patients presented the GG genotype19 (42.2\%) the GT, and 2 (4.4\%) the TT. The AI treatment was Anastrazole for 35 patients (77.8\%) and Letrozole for the others (n=1022.2\%). Osteoporosis was significantly associated with the GG genotype (p=0.001). Treatment discontinuation (TD) was observed in 6 cases (13.3\%). The only parameter able to predict TD was the appearance of severe arthralgia/myalgia (Odds Ratio, OR=23.75p=0.009), when adjusted for age and AI treatment. Conclusion: Our results suggest that CYP19A1 polymorphic variants may influence susceptibility to develop AI-related side effects. Further prospective studies are needed to confirm the role of the aromatase gene (CYP19A1) polymorphisms in predicting adverse effects to AI-based therapy.Adjuvant hormonal therapyrs4646aromatase inhibitorbreast cancerCYP19A1single nucleotide polymorphismsArticleWOS:000373481300004